Global

Jun 01, 2011
Pharmaceutical Executive
Why has the EU still not managed to update its rules on information about medicines?
May 01, 2011
Pharmaceutical Executive
The EU is largely powerless when it comes to policies over pricing and reimbursement
May 01, 2011
Pharmaceutical Executive
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
Jul 01, 2010
Pharmaceutical Executive
As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.
May 01, 2010
Pharmaceutical Executive
The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.
Aug 11, 2009
By Pharmaceutical Executive Editors
11 August
Jul 22, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.
Jul 08, 2009
By Pharmaceutical Executive Editors
UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.
Jun 17, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.
May 06, 2009
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.
native1_300x100
lorem ipsum